BCAB
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Context Therapeutics amended its licensing agreement with BioAtla for CT-202May 18, 2026
- BioAtla to present clinical data for Mecbotamab Vedotin (BA3011) in soft tissue sarcoma at SITC 2025Oct 6, 2025
- BioAtla presents Phase 2 data for Ozuriftamab Vedotin showing promising antitumor activity in HPV+ OPSCCJun 2, 2025